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PKCP-21-activated kinases (PAKs) are serine/threonine kinases comprising six isoforms divided in two groups,
group-I (PAK1–3)/group-II (PAK4–6)whichplay important roles in cell cytoskeletal dynamics, survival, secretion
and proliferation and are activated by diverse stimuli. However, little is known about PAKs ability to be activated
by gastrointestinal (GI) hormones/neurotransmitters/growth-factors.Weused rat pancreatic acini to explore the
ability of GI-hormones/neurotransmitters/growth-factors to activate Group-I-PAKs and the signaling cascades
involved. Only PAK2 was present in acini. PAK2 was activated by some pancreatic growth-factors [EGF, PDGF,
bFGF], by secretagogues activating phospholipase-C (PLC) [CCK, carbachol, bombesin] and by post-receptor stim-
ulants activating PKC [TPA], but not agents only mobilizing cellular calcium or increasing cyclic AMP. CCK-
activation of PAK2 required both high- and low-afﬁnity-CCK1-receptor-state activation. It was partially reduced
by PKC- or Src-inhibition, but not with PI3K-inhibitors (wortmannin, LY294002) or thapsigargin. IPA-3, which
prevents PAK2 binding to small-GTPases partially inhibited PAK2-activation, as well as reduced CCK-induced
ERK1/2 activation and amylase release induced by CCK or bombesin. This study demonstrates pancreatic acini,
possess only one Group-I-PAK, PAK2. CCK and other GI-hormones/neurotransmitters/growth-factors activate
PAK2 via small GTPases (CDC42/Rac1), PKC and SFK but not cytosolic calcium or PI3K. CCK-activation of PAK2
showed several novel features being dependent on both receptor-activation states, having PLC- and PKC-
dependent/independent components and small-GTPase-dependent/independent components. These results
show that PAK2 is important in signaling cascades activated by numerous pancreatic stimuli which mediate
their various physiological/pathophysiological responses and thus could be a promising target for the develop-
ment of therapies in some pancreatic disorders such as pancreatitis.
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sen).1. Introduction
The p21-activated kinases (PAKs) are a family of serine threonine ki-
nases that are one of the main effectors for the small Rho GTPases,
Cdc42 and Rac [1–3]. The PAK family consists of six members that are
segregated into two subgroups (Group I and Group II) based on se-
quence homology [1,3–6]. Group-I-PAKs (PAK 1–3) are themost exten-
sively studied and play an important role in signaling for many cellular
processes, such as regulation of cell survival, apoptosis, cell motility,
tumorigenesis, protein synthesis, glucose homeostasis, secretion and
cellular proliferation [1–5,7–14]. The Group-I-PAKs normal tissue ex-
pression varies greatly between the three isoforms [15,16]. PAK2 is
expressed in a wide variety of different tissues and can be thought of
as ubiquitously expressed. In contrast, PAK1 has a slightly more re-
served distribution, with high levels of PAK1 in tissues such as muscle,
spleen, heart and liver. PAK3 has a much more restricted expression,
being predominantly expressed in the brain, although recent reports
have identify it in enteroendocrine cells [17]. Studies demonstrate that
PAKs play an important signaling role in various tissues for a wide
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[20], chemokines [21], growth factors [22–29], cellular stress [9,10], ra-
diation [30], and with activation of some G-protein-coupled receptors
[26,31]. However, there is little information on the activation of
Group-I-PAKs by gastrointestinal (GI) hormones/neurotransmitters
and GI growth factors in normal GI tissues. Pancreatic acinar cells pos-
sess receptors for a large number of GI hormones/neurotransmitters
and growth factors and are an excellent model to study their cellular
basis of action, because the agents also alter cellular function activating
numerous cellular signaling cascades [32–34]. At present it is unclear if
any Group-I-PAKs occur in pancreatic acinar cells, although it is known
that at least 2 types (PAK1, 3) occur in pancreatic islets [16,35,36]. It is
also unknown whether activation of any of the GI hormones/neuro-
transmitter receptors or GI growth factor receptors in these cells acti-
vates acinar cell PAKs, or if present, any information on the cellular
signaling mechanisms involved.
To address this question in the case of the PAKs, in the present study
we sought to determine whether the three members of the Group-I-
PAKs were present in rat pancreatic acinar cells and if they are involved
in mediating the cellular signaling of gastrointestinal hormones/neuro-
transmitters and of various gastrointestinal growth factors, which are
known to alter pancreatic acinar cell function. Particular attention was
paid to the GI hormone/neurotransmitter, cholecystokinin (CCK), be-
cause this is a well-studied physiological regulator of pancreatic acinar
cell function with effects on secretion, growth, and enzyme synthesis
as well as playing a prominent role in a number of pancreatic acinar
cell pathophysiological processes [37,38].
2. Materials and methods
2.1. Materials
Male Sprague–Dawley rats (150–250 g) were obtained from the
Small Animals Section, Veterinary Resources Branch, National Institutes
of Health (NIH), Bethesda, MD. PAK1 recombinant protein was from
Abnova (Walnut, CA). Recombinant PAK2 protein active was from Ac-
tive Motif (Carlsbad, CA). Pak 3 recombinant human protein was from
Life Tech. (Grand Island, NY). Pak 4 recombinant human protein was
from MyBIosource (San Diego, CA). Rabbit anti-PAK1, rabbit anti-
phospho-PAK1/2 (Thr402/423), and nonfat dry milk were purchased
from Cell Signaling Technology, Inc. (Beverly, MA). Stabilized goat
anti-rabbit IgG peroxidase conjugated was from Pierce Biotechnology,
Inc. (Rockford, IL). Goat PAK2 antibody, and anti-goat-HRP-conjugate
antibodies were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).
Pak 3 antibody was from Abcam (Cambridge, MA). Tris/HCl pH 8.0
and 7.5 were from Mediatech, Inc. (Herndon, VA). 2-Mercaptoethanol,
protein assay solution, sodium lauryl sulfate (SDS) and Tris/Glycine/
SDS (10×) were from Bio-Rad Laboratories (Hercules, CA). MgCl2,
CaCl2, Tris/HCl 1 M pH 7.5 and Tris/Glycine buffer (10×) were from
Quality Biological, Inc. (Gaithersburg, MD). PAK 6 Recombinant protein,
minimal essential media (MEM) vitamin solution, amino acids 100×,
Dulbecco's phosphate buffered saline (DPBS), glutamine (200 mM),
Tris–Glycine gels, L-glutamine, and fetal bovine serum (FBS) were
from Invitrogen (Carlsbad, CA). COOH-terminal octapeptide of cho-
lecystokinin (CCK), hepatocyte growth factor (HGF), bombesin,
insulin-like growth factor 1 (IGF-1), basic ﬁbroblast growth factor
(bFGF), vasoactive intestinal peptide (VIP), endothelin and secretin
were from Bachem Bioscience Inc. (King of Prussia, PA). CCK-JMV-180
(CCK-JMV)was obtained fromResearch Plus Inc. (Bayonne, NJ). Epider-
mal growth factor (EGF), thapsigargin, platelet-derived growth factor
(PDGF), vascular endothelial growth factor (VEGF), PAK5 active protein,
deoxycholic acid and P21-activated kinase inhibitor 3 (IPA-3) were
from Calbiochem (La Jolla, CA). Carbachol, insulin, dimethyl sulfoxide
(DMSO), 12-O-tetradecanoylphobol-13-acetate (TPA), L-glutamic acid,
glucose, fumaric acid, pyruvic acid, trypsin inhibitor, HEPES, TWEEN®
20, Triton X-100, GFX (GFX109203X), phenylmethanesulfonylﬂuoride(PMSF), ethylenediaminetetraacetic acid (EDTA), ethylene glycol
tetraacetic acid (EGTA), sucrose, sodium-orthovanadate, and sodium
azide were from Sigma-Aldrich, Inc. (St. Louis, MO). Albumin standard
and Super Signal West (Pico, Dura) chemiluminescent substrate were
from Pierce (Rockford, IL). Phadebas Amylase test was from Magle Life
Science (Lund, Sweden). Protease inhibitor tablets were from Roche
(Basel, Switzerland). Puriﬁed collagenase (type CLSPA) was from
Worthington Biochemicals (Freehold, NJ). Nitrocellulose membranes
were from Schleicher and Schuell Bioscience, Inc. (Keene, NH). L-
364,718 (3S(−)-N-(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-
benzodiazepine-3-yl-1H-indole-2-carboxamide)) was from Merck,
Sharp and Dohme (West Point, PA). YM022 ((R)-1-[2,3-dihydro-1-
(2′-methyl-phenacyl)-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-
(3-methylphenyl)urea), SR27897 (1-[[2-(4-(2-chlorophenyl)-thiazol-
2-yl)aminocarbonyl] indolyl]acetic acid) and PIR 3,5 (IPA-3 inactive
control) were from Tocris Bioscience (Ellisville, MO). Albumin bovine
fraction V was from MP Biomedical (Solon, OH). NaCl, KCl and
NaH2PO4 were fromMallinckrodt (Paris, KY).
2.2. Methods
2.2.1. Pancreatic acini preparation
Pancreatic aciniwere obtained by collagenase digestion as previous-
ly described [34]. Standard incubation solution contained 25.5 mM
HEPES (pH 7.45), 98mMNaCl, 6 mMKCl, 2.5 mMNaH2PO4, 5mM sodi-
um pyruvate, 5 mM sodium glutamate, 5 mM sodium fumarate,
11.5 mM glucose, 0.5 mM CaCl2, 1 mM MgCl2, 1 mM glutamine, 1%
(w/v) albumin, 0.01% (w/v) trypsin inhibitor, 1% (v/v) vitamin mixture
and 1% (v/v) amino acid mixture.
2.2.2. Acini stimulation
After collagenase digestion, dispersed acini were pre-incubated
in standard incubation solution for 2 h at 37 °C as described previ-
ously [34,39]. After pre-incubation 1 ml aliquots of dispersed acini
were incubated at 37 °C with or without stimulants. Cells were
lysed in lysis buffer (50 mM Tris/HCl pH 7.5, 150 mM NaCl, 1% Triton
X-100, 1% deoxycholate, 0.1% sodium azide, 1 mM EGTA, 0.4 mM
EDTA, 0.2 mM sodium orthovanadate, 1 mM PMSF, and one protease
inhibitor tablet per 10 ml). After sonication, lysates were centrifuged
at 10,000× g for 15 min at 4 °C and protein concentration was mea-
sured using the Bio-Rad protein assay reagent.
2.2.3. Inhibition experiments
Weused small inhibitormolecules to identify upstreamactivators of
the CCK/TPA-mediated activation of PAK2. Isolated acini were preincu-
bated for 15 min with IPA-3 that prevents binding of CDC42 to group I
PAKs and its inactive analog PIR 3,5 as a control;with the PI3K inhibitors
wortmannin or LY294002, also for 15 min and with the Src inhibitor,
PP2, and its inactive analog PP3 for 1 h. Cells were then treated for
3 min with physiological (0.3 nM) or supraphysiological (100 nM) con-
centrations of CCK and alsowith TPA (5min, 1 μM),with untreated cells
for each pretreatment used as controls. After incubation, cells were
processed as stated above.
2.3. Western blotting
It was performed as described previously [40]. Whole cell lysates
were subjected to SDS-PAGE using 4–20% Tris–Glycine gels. After elec-
trophoresis, proteins were transferred to nitrocellulose membranes.
Membranes were blocked in blocking buffer (50 mM Tris/HCl pH 8.0,
2 mM CaCl2, 80 mM NaCl, 0.05% Tween® 20, 5% non fat dry milk) at
room temperature for 1 h. Membranes were then incubated with pri-
mary antibody overnight at 4 °Cunder constant agitation at antibody di-
lutions suggested by the supplier. After primary antibody incubation
membranes were washed twice in blocking buffer for 4 min and then
incubated with HRP-conjugated secondary antibody (anti-mouse,
Fig. 1. Speciﬁcity of the antibodies used in the study. Lysates from pancreatic acini and
equal amounts (5 μg) of human recombinant PAK family members (PAK 1–6) or control
cell lysates (C6, COS) were detected by Western blotting with speciﬁc anti-PAK1, anti-
PAK2 and anti-PAK3 antibodies (Cell signaling = CS), Panels A, B and C; or with a speciﬁc
anti-phospho Pak1 (T423)/PAK2 (T402) antibody (Cell signaling), Panel D. These results
are representative of 4 other experiments.
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1 h at room temperature under constant agitation. Membranes were
then washed again twice in blocking buffer for 4 min, twice in washing
buffer (50mMTris/HCl pH8.0, 2mMCaCl2, 80mMNaCl, 0.05% Tween®
20) for 4 min, incubated for 4 min with chemiluminescence detection
reagents and ﬁnally exposed to Kodak Biomax ﬁlm (XAR, MS or MR).
The intensity of the protein bands was measured using Kodak ID
Image Analysis, which were assessed in the linear detection range.
When re-probing was necessary membranes were incubated in a strip-
ping buffer (Pierce, Rockford, IL) for 30 min at room temperature,
washed twice for 10 min in washing buffer, blocked for 1 h in blocking
buffer at room temperature and re-probed as described above.
2.3.1. Amylase release
In order to study the effect of PAK2 activation in the stimulation of
amylase release in rat pancreatic acinar cells, isolated acini were pre-
incubated with either no additions, or with 40 μM IPA3 or its inactive
analog Pir 3,5, and then subsequently incubated with CCK at either a
low (0.01 nM) ormaximal (0.1 nM) concentrations andwith amaximal
bombesin concentration (10 nM). Amylase release wasmeasured using
the procedure published previously [41,42]. Amylase activitywas deter-
mined after a 30 min incubation using the Phadebas reagent and was
expressed as percentage of the total cellular amylase released into the
extracellular medium during the incubation [41,42].
2.3.2. Statistical analysis
All experiments were performed at least 5 times. Data are presented
as mean ± SEM and were analyzed with the non-parametric Kruskal–
Wallis analysis using the GraphPad 5.0 software. p values b0.05 were
considered signiﬁcant. Curve ﬁtting, EC50 and tmax were also calculated
using the GraphPad 5.0 software.
3. Results
3.1. Speciﬁcity of the antibodies used in the study and presence of PAK2 in
pancreatic acini
To assess the possible presence of Group I PAKs (i.e., PAK 1, 2, 3) in
pancreatic acinar cells and also to determine the speciﬁcity of the anti-
bodies to be used in this study, whole pancreatic acinar lysates, in par-
allel with human recombinant samples of the 6 PAK family members
(PAK1–PAK6) andwith control cell lysates (C6 and COS cells)were blot-
ted with antibodies reported to be speciﬁc for PAK1, PAK2 and PAK3
(Fig. 1, A–C). Each of the three antibodies was speciﬁc for their respec-
tive PAK. We observed only PAK2 was present in pancreatic acinar
cells (Fig. 1, B, Lane 1). Moreover, using a phospho (T423/402) PAK1/2
antibody (Fig. 1D) in stimulated pancreatic acinar cells and in rat glioma
cell line C6 cells, reported to have both PAK1 and PAK2 [15]we detected
a double band corresponding to PAK1 and PAK2 in the C6 cells (Fig. 1D,
Lane 3), but only detected a single band corresponding to phospho
(T402) PAK2 (Fig. 1D, Lane 2) in the pancreatic acinar cells. These re-
sults demonstrate that, under the experimental conditions used in our
study the only Group-I-PAKs activated by the various stimuli in the pan-
creatic acini was phospho-PAK2.
3.2. Ability of various pancreatic secretagogues and pancreatic growth
factors to stimulate PAK2 phosphorylation (pT402) in rat pancreatic acini
In order to establishwhether PAK2 is activated by known pancreatic
secretagogues or growth factors [33], rat pancreatic acini were incubat-
ed in the absence and presence of several gastrointestinal hormones
(CCK, carbachol, bombesin, secretin, VIP, endothelin) known to interact
with speciﬁc G protein-coupled receptors in pancreatic acini [33]. As a
measurement of PAK2 activity, we analyzed the phosphorylation of
T402PAK2, which has been shown to be essential for PAK2 protein ki-
nase activity, as well as reﬂecting its degree of activation and has beenwidely used to assess its activation in other studies [43–46]. The pancre-
atic secretagogues that activate phospholipase C (bombesin, carbachol
and CCK) stimulated an increase in phospho-(T402)PAK2 (222 ± 53,
220 ± 56, 408 ± 104 of control, respectively, all p b 0.05 vs control)
(Fig. 2A, Rows 4–6; Table 1). VIP and secretin, which activate adenylate
cyclase in rat pancreatic acini at the concentrations used [33,47], did not
increase phosphorylation of (T402) PAK2 (Fig. 2A, Rows 2 and 3;
Table 1). Endothelin-1 (ET-1), which interacts with ET-1 and ET-3
Fig. 2. Ability of various pancreatic secretagogues and pancreatic growth factors to stimu-
late PAK2 phosphorylation (pT402) in rat pancreatic acini. Panel A: Ability of CCK, carba-
chol, bombesin, secretin, VIP or endothelin I to activate pT402 PAK2 in isolated
pancreatic acini. Isolated pancreatic acini were incubated in the absence or presence of
CCK (100 nM), carbachol (10 μM), bombesin (1 nM), secretin (10 nM), VIP (10 nM) or
endothelin 1 (10 nM) for 1min, and then lysed. The cell lysateswere subjected toWestern
blotting and analyzed using anti-pT402 PAK2 and, as loading control, anti-total PAK2.
Bandswere visualized using chemiluminescence and quantiﬁed by densitometry. Top: Re-
sults of a representative blot of 5 independent experiments are shown. Bottom: Means ±
S.E. of 5 independent experiments. Results are expressed as % of basal stimulation of the
control group taking total PAK2 as a loading control. *p b 0.05 compared to the control.
Panel B: Ability of insulin, IGF-1, HGF, EGF, bFGF and PDGF to activate PAK2 in the pancre-
atic acini. Isolated pancreatic acini were incubated in the absence or presence of insulin
(1 μM, 10 min), EGF (10 nM, 5 min), PDGF (100 ng/ml, 10 min), bFGF (100 ng/ml,
5 min), IGF (100 nM, 10 min) and HGF (1 nM) for 10 min, and then lysed. The lysates
were subjected to Western blotting and analyzed using anti-pT402 PAK2 antibody and,
as loading control, anti-Total PAK2. Bands were visualized using chemiluminescence and
quantiﬁed by densitometry. Results of a representative blot of 5 independent experiments
are shown. * p b 0.05 compared to the control. Panel C: Ability of selective CCKA or CCKB
receptor agonist/antagonists to alter PAK2 activation in pancreatic acini. Isolated pancre-
atic acini were incubated in the absence or presence of CCK (100 nM), the CCKB agonist,
gastrin (10 nM) or the CCKA receptor agonist, A71378 (30 nM) for 1min (left blot), or pre-
incubated for 5min in the presence of the CCKB antagonist YM022 (1 μM), the CCKA antag-
onists SR27897 (1 μM) or L364,718 (1 μM) and then after the additional presence of CCK
(100 nM) for 3min (right blot), the cells were lysed. PAK2 kinase activity was determined
as outlined in Materials and methods and Western blots were analyzed using anti-pT402
PAK2 and, as loading control, anti-Total PAK2.
Table 1
T402 PAK2 kinase phosphorylation characteristics and interactions of PAK2 in rat pancre-
atic acinia.
Variable pT402 phosphorylation
Stimulation by pancreatic secretagoguesb
Yes CCK, carbachol, bombesin
No Secretin, Endothelin-1, VIP
Stimulation by pancreatic growth factorsb
Yes EGF, bFGF, PDGF
No Insulin, IGF-1, HGF
Stimulation by post-receptor activatorsd
Yes TPA
No Thapsigargin, A23187
Potency/time-course
EC50 of CCK (nM)c 0.44 ± 0.05
EC50 of CCK-JMV (nM)c 0.18 ± 0.14
CCK-stimulated PAK2 activation
inhibited (0.3 nM)e
Yes: Inhibitor: SFK (PP2), GTPase
to PAK2 (IPA-3), GFX (PKC)
No: Inhibitor PI3K (wortmannin,
LY294002),
Ca++ (thapsigargin)
CCK-stimulated PAK2 activation
inhibited (100 nM)
Yes: Inhibitor: GTPase to PAK2 (IPA-3),
GFX (PKC)
No: Inhibitor SFK (PP2), PI3K
(wortmannin,
LY294002), Ca++ (thapsigargin)
a Results are calculated from the data shown in Figs. 2–5.
b Concentration and incubation times are reported in Fig. 2.
c Concentrations and incubation time are reported in Fig. 3.
d Concentration and incubation times are reported in Fig. 5.
e Concentration and incubation times are reported in Fig. 6.
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cades nor activate adenylate cyclase [48] did not produce any effect
upon T402 PAK2 phosphorylation (Fig. 2A, Row 7; Table 1).Of six growth factors known to alter pancreatic acinar cell function,
which were tested [33], EGF (195 ± 28 of control p b 0.05), bFGF
(228 ± 37 of control p b 0.05) and PDGF (240 ± 44 of control
p b 0.05) were able to stimulate PAK2 threonine 402 phosphorylation,
whereas IGF and HGF had no effect (Fig. 2B, Table 1). Insulin caused a
210 ± 44 increase in T402 PAK2 phosphorylation, however this effect
did not quite reach statistical signiﬁcance (p = 0.08) (Fig. 2B, Row 2;
Table 1).
In order to determine if the CCK stimulating effect on pT402 PAK2
phosphorylation was due to the presence/activation of CCK1 or CCK2
receptors in the acinar cell suspension, isolated acinar cells were ﬁrst
incubated with either CCK, or the selective CCKB agonist gastrin, or a
known selective CCK1 receptor agonist (A71378) [49] (Fig. 2C, Lanes
1–4). Gastrin did not produce any increase in pT402 PAK2 phosphor-
ylation, and the CCK activation of PAK2 was mimicked by the incuba-
tion of the cells with the speciﬁc CCK1 receptor agonist, A71378
(Fig. 1C, Lanes 2–4). Moreover, when the acinar cells were incubated
with CCK and two different CCK1 receptor antagonists [L364, 718 or
SR27897] [50,51] the increment in pT402 PAK2 phosphorylation ob-
served in the sole presence of CCK was largely inhibited, but not in
the presence of the CCK2 receptor antagonists YM022 [50] (Fig. 2,
Panel C, Lanes 5–10). These results demonstrate that the observed ef-
fect of CCK in pT402 PAK2 phosphorylation is only due to the activa-
tion of CCK1 receptors.
3.3. Dose–response effect of CCK and CCK-JMV on T402 PAK2
phosphorylation in rat pancreatic acini
As CCK has an important role in both the normal physiology and the
pathophysiology of the pancreas [33,38,52,53], we focused our study in
the activation of PAK2 exerted by this hormone in rat pancreatic acini.
Increasing concentrations of CCK produced an increase in T402 phos-
phorylation of PAK2, detectable at 0.01 nM concentration (Fig. 3), max-
imal stimulation occurred with 100 nMCCK (452± 70% of control) and
CCK's half-maximal effect (EC50) occurred with 0.44 nM ± 0.05 nM
(Fig. 3, Table 1). The CCK1 receptor in pancreatic acini can exist in two
different activation states, a low- and a high-afﬁnity state, and the
Fig. 3. Dose–response effect of CCK and CCK-JMV on PAK2 kinase phosphorylation in
rat pancreas acini. Isolated pancreatic acini were incubated in the absence or pres-
ence of CCK and CCK-JMV (at the indicated concentrations) for 3 min, and then
lysed. Western blots were analyzed using anti-pT402 PAK2 antibody and, as loading
control, anti-Total PAK2. Bands were visualized using chemiluminescence and quan-
tiﬁed by densitometry. Top: Results of a representative blot of 5 independent exper-
iments are shown. Bottom: Means ± S.E. of 5 independent experiments. Results are
expressed as % of maximal CCK stimulation (CCK 100 nM: 904 ± 140% of control). *
p b 0.05 compared to the control group.
Fig. 4. Time course of CCK and EGF stimulation of PAK2 T402 phosphorylation in rat pan-
creatic acini. Isolated pancreatic acini were incubated in the absence or presence of CCK
(100 nM) or EGF (10 nM) for the indicated times, and then lysed. Western blots were an-
alyzed using anti-pT402 PAK2 and, as loading control, anti-Total PAK2. Bandswere visual-
ized using chemiluminescence and quantiﬁed by densitometry. Top: Results of a
representative blot of 5 independent experiments are shown. Bottom: Means ± S.E. of 5
independent experiments. Results are expressed as % of basal stimulation of the control
group. * p b 0.001 compared to the control group (i.e., 0 time).
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cades [38,54–56]. In order to determine the contribution of each activa-
tion receptor state to the activation of PAK2 by CCK, pancreatic acini
were incubated in the presence of increasing concentrations of CCK-
JMV, known to be an agonist of theCCK1 high afﬁnity state and an antag-
onist of the low afﬁnity CCK1 receptor state in the rat pancreatic acini
[54,56,57]. CCK-JMV stimulated threonine 402 phosphorylation of
PAK2 in a monophasic manner with concentrations from 100 nM to
1000 nM (Fig. 3) with an EC50 of 0.18 ± 0.14 nM (Fig. 3, Table 1), and
therefore was 2.5-times more potent than CCK. CCK-JMV caused 26%
of the maximal stimulation of pT402 PAK2 phosphorylation caused by
CCK (Fig. 3). These results support the conclusion that CCK stimulation
of PAK2 kinase activation is mediated 26% by the high afﬁnity state
CCK1 receptor and 74% by activation of the low afﬁnity CCK1 receptor
state. At a CCK concentration of 100 nM, a concentration that activates
both CCK receptor states, CCK produced the maximal stimulation of
T402 PAK2 phosphorylation, thus it was selected for use in the rest of
the study.3.4. Time course of CCK and EGF stimulation of T402 PAK2 phosphorylation
in rat pancreatic acini
Stimulation of T402 PAK2 by CCK was time-dependent, with a
signiﬁcant increment after 1-minute incubation time (275 ± 17% of
control, p b 0.05), and maximum after 3 min (298 ± 26% of control,
p b 0.05) (Fig. 4). The increase in phosphorylation of phospho-T402
PAK2 by CCK was maintained in time and lasted over 15 min (all
p b 0.05) (Fig. 4).
Because some of the growth factors studied stimulated T402 PAK2
phosphorylation, the ability of EGF, to stimulate PAK2 T402 phosphory-
lation at different times, was studied (Fig. 4). EGF produced, as in the
case of CCK, a rapid and maximum increase (1 min: 300 ± 30% of con-
trol) in PAK2 pT402 phosphorylation (Fig. 4), and the increase was not
maintained for longer than 3min. EGF stimulation of pT402 PAK2 phos-
phorylation had a rapid decrease compared with CCK (Fig. 4).3.5. Effect of post-receptor stimulants, PKC inhibition or Ca2+ depletion on
T402 PAK2 kinase phosphorylation by CCK and TPA
When the ability of post-receptor stimulants to stimulate threonine
402 phosphorylation of PAK2 was studied, the PKC activating agent,
TPA, produced a signiﬁcant increment in threonine 402 phosphoryla-
tion of PAK2 (TPA= 635 ± 97% of control p b 0.05). However, in calci-
um containing medium neither the cellular calcium-mobilizing agent,
thapsigargin (TG) (180 ± 40% of control) nor the calcium ionophore,
A23187 (209 ± 35%), signiﬁcantly increased PAK2 phosphorylation.
The combination of the calcium mobilization agent, thapsigargin, or
the calcium ionophore, A23187, with the PKC activator, TPA, did not
cause greater activation than with any of these agents alone (Fig. 5,
Panel A, Rows 1–7; Table 1).
We next examined whether CCK-induced activation of PKC or in-
crease in intracellular calcium were needed for its ability to cause
pT402 threonine phosphorylation of PAK2 in pancreatic acini (Fig. 5,
Panel B, Rows 1–12). To determine the role of intracellular calcium
changes, [Cai], pancreatic acinar cells were pretreated for 1 h in a
calcium-free medium with thapsigargin (10 μM), an agent that speciﬁ-
cally inhibits the endoplasmic reticulum Ca2+-ATPase and depletes cal-
cium from intracellular compartments in a calcium free medium [34].
These conditions have been previously shown to completely inhibit
the [Ca2+i] increase stimulated by CCK in rat pancreatic acinar cells
[34]. In order to examine the implication of PKC in the CCK stimulated
threonine 402 PAK2 phosphorylation, isolated acinar cells were treated
for 1 h with a general PKC inhibitor GFX109203X [34] prior to incuba-
tion with CCK or TPA. When PKCs activation was inhibited, the incre-
ment in the threonine phosphorylation of PAK2 was signiﬁcantly
reduced in the case of CCK or completely inhibited in the case of TPA
(CCK alone: 515 ± 73% of control, p b 0.05 vs control; CCK + GFX:
245 ± 50% of control, p b 0.05 vs CCK alone; TPA alone: 319 ± 45% of
control, p b 0.05 vs control; TPA + GFX: 100 ± 26% of control, p b 0.05
vs TPA alone) (Fig. 5, Panel B, Rows 1–6). Inhibition of CCK-stimulated
increases in intracellular Ca2+ did not signiﬁcantly decrease the pT402
threonine phosphorylation of PAK2 by CCK (CCK alone: 515 ± 73% of
control, p b 0.05 vs control; TG + CCK: 403 ± 86% of control) (Fig. 5,
Fig. 5. Effect of post-receptor stimulants, PKC inhibition or Ca2+ depletion on pT402 PAK2
phosphorylation by CCK and TPA. Panel A: Effect of the calcium ionophore A23187 (1 μM),
TPA (1 μM), Thapsigargin (TG) (1 μM), or CCK (100 nM), on PAK2 phosphorylation [all for
5 min, except CCK for 3 min]. Top: Results of a representative blot of 5 independent experi-
ments are shown.Bottom:Means±S.E. of 5 independent experiments. Results are expressed
as % of basal stimulation of the control group. * p b 0.05 compared to the control group. Panel
B: Effect of PKC inhibition or Ca2+ depletion on pT402 PAK2 CCK- and TPA-induced phos-
phorylation. Isolated acini were preincubated for 2 h, alone or in the additional presence of
GF109203X (5 μM, 1 h), Thapsigargin (TG) (1 μM, 1 h) or both and then incubated with or
without 100 nMCCK or 1 μMTPA for 3 or 5min, respectively. Top: Results of a representative
blot of 5 independent experiments are shown.Bottom:Means±S.E. of 5 independent exper-
iments. Results are expressed as % of basal stimulation of the control group. * p b 0.05 com-
pared to the control group, ^ p b 0.05 vs its own control, $ p b 0.05 vs CCK-alone, #
p b 0.05 vs TPA alone.
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an additive effect in the inhibition of basal T402 PAK2 phosphorylation
(26 ± 11% of control, p b 0.05 vs control) and also inhibited the phos-
phorylation induced by CCK (CCK alone: 515 ± 73% of control,
p b 0.05 vs control; TG + GFX + CCK: 138 ± 31% of control, p b 0.05
vs CCK-alone) and with TPA, where no signal of phospho-T402 PAK2
was detected in any of the experiments (Fig. 5, Panel B, compare Rows
9–12, 4–6, 7–9).
3.6. SFKs and CDC42/Rac1, but not PI3K are upstream activators of PAK2 in
pancreatic acinar cells
Oncewedetermined the involvement of PKC in activation of PAK2,we
wanted to knowwhether CCK- and TPA-induced PAK2 activationwas de-
pendent on stimulation of the small GTPases (CDC42 and Rac1), SFK or
PI3K in pancreatic acini (Fig. 6, Panels A–C, Rows 1–12). To determine
their possible involvement, isolated acinar cells were treated, prior to in-
cubation with CCK or TPA, either for 1 h with the SFK inhibitor PP2
(10 μM) [58] or for 15 min with the PI3K inhibitors wortmannin [57]
(1 μM) or the PAK2 inhibitor, IPA-3 (40 μM) that binds covalently to the
Group-I-PAKs regulatory domain, preventing binding to Cdc42 and/or
Rac1 [15,59] and that has proven speciﬁcity for Group I PAKS [59]. We
used IPA-3 at this incubation time (t = 15 min) and concentration
(40 μM) because in a previous study [8] it was shown to efﬁcaciously in-
hibit PAK activity under these incubation conditions. The PI3K inhibitor,
LY294002 (100 μM), and the inactive analogs for PP2 and IPA-3, PP3
(10 μM) and Pir-3,5 (40 μM) were also used to insure speciﬁcity.
When PI3K activation was inhibited with wortmannin or LY294002,
the basal pT402 threonine phosphorylation of PAK2 was not affected
(Fig. 6, Panel C, Lanes 5 and 9). Furthermore, the increment in the thre-
onine phosphorylation of PAK2was not signiﬁcantly reduced in the case
of both CCK concentrations or TPA (CCK 0.3 nM +Wort: 82 ± 15% of
CCK 0.3 nM alone, p b 0.05; CCK 100 nM + Wort: 99 ± 21% of CCK
100 nM alone, p b 0.05; TPA +Wort: 79 ± 20% of TPA alone, p b 0.05)
(Fig. 6, Panel C, Rows 6–8). Preincubation with 100 μM LY294002 con-
ﬁrmed the results obtained with wortmannin (CCK 0.3 nM + Wort:
86 ± 39% of CCK 0.3 nM alone, p b 0.05; CCK 100 nM + Wort: 89 ±
26% of CCK 100 nM alone, p b 0.05; TPA + Wort: 90 ± 18% of TPA
alone, p b 0.05) (Fig. 6, Panel C, Rows 10–12).
Inhibition of SFK did not signiﬁcantly decrease either the basal
pT402 threonine phosphorylation of PAK2 (95 ± 8% of control) or its
100 nM CCK-stimulated phosphorylation (CCK 100 nM + PP2: 90 ±
11% of CCK 100 nM alone). However, preincubation with PP2 decreased
0.3 nM CCK- and TPA-stimulated phosphorylation (CCK 0.3 nM+ PP2:
51 ± 14% of CCK 0.3 nM alone, p b 0.05; TPA + PP2: 38 ± 3% of TPA
alone, p b 0.05) (Fig. 6, Panel B, Rows 1–12). The inactive control PP3
did not have any effect upon PAK2 phosphorylation or upon the positive
control (Fig. 6, Panel B, Rows 9–12).
Prevention of the binding of the small GTPases, CDC42 and/or Rac1
by preincubation with the speciﬁc PAK inhibitor IPA-3 [15], resulted in
a reduction of basal activation levels of PAK2 (32 ± 6% of control,
p b 0.05 vs control), and also decreased its CCK-induced activation
(CCK 0.3 nM + IPA3: 30 ± 9% of CCK 0.3 nM alone, p b 0.05; CCK
100 nM + IPA3: 45 ± 4% of CCK 100 nM alone, p b 0.05) and TPA-
induced activation (TPA + IPA3: 39 ± 9% of TPA alone, p b 0.05)
(Fig. 6, Panel A, Rows 1–12). That this IPA-3 inhibitory effect was not
due to a nonspeciﬁc effect on PAK2 activation is supported by the results
with the inactive control Pir-3, 5 which did not have any effect upon
PAK2 activation (Fig. 6, Panel A, Rows 9–12). This concentration of
IPA-3 produced a 70% of PAK2 inhibition.
3.7. Effects of PAK2 inhibition in ERK1/2 activity
Preincubation with 40 μM IPA-3, a concentration that reduced PAK
activity by a 70% did not affect the basal phosphorylation of p42/44
(89 ± 18% of basal, p b 0.05) (Fig. 7). However, IPA-3 preincubation
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(64 ± 4% of CCK 0.3 nM alone, p b 0.05) (Fig. 7).3.8. Effects of PAK2 inhibition in amylase release
To investigate the possible effect of PAK2 inhibition on enzyme
secretion, acini were incubated with two pancreatic secretagogues
(i.e., CCK at two concentrations and bombesin) with or without the
active PAK2 inhibitor or its inactive control analog (Table 2). The
two CCK concentrations or bombesin alone resulted in a stimulation
of enzyme secretion, as previously reported in numerous studies
[60–62] with 0.01 nM CCK causing a 313 ± 57% increase in amylaseFig. 7. Effect of the PAK2 inhibitor, IPA-3 and its inactive analog PIR 3,5 on the ability of a
physiological 0.3 nM concentration of CCK to activate ERK1/2 . Rat pancreatic acinar cells
were processed as stated in Fig. 6. Membranes were analyzed using anti p-Y202/204 p42/
44. An antibody detecting total amount of ERK1/2 was used to verify loading of equal
amounts of protein. The bands were visualized using chemoluminescence and quantiﬁca-
tion of phosphorylation was assessed using scanning densitometry. Both a representative
experiment of 4 others (top panel) and the means of all the experiments (bottom panel)
are shown. * p b 0.05 vs control, ∞ p b 0.05 vs Pir 3,5 alone and $ p b 0.05 comparing CCK
stimulation vs stimulants pre-incubated with IPA-3 or Pir 3,5, respectively.release, 0.1 nM CCK a 413 ± 11% and bombesin causing an increase
of 401 ± 21%(Table 2). Preincubation with 40 μM IPA3, which
inhibited PAK2 activity by approximately 70% (Fig. 6A) reduced the
increase in amylase release induced by both concentrations of CCK
by a 63% of maximal CCK stimulation and that induced by bombesin
by 55% of themaximal bombesin-induced stimulation. Preincubation
with the IPA3 inactive analog Pir3,5 (40 μM) had no effect on stimu-
lated enzyme secretion (Table 2) supporting the speciﬁcity of IPA-3
in inhibiting CCK- and bombesin-induced amylase release.Fig. 6. Effect of the inhibition of Src, PI3K and the binding of GTPases to PAK2 on the ability
of physiological (0.3 nM) and supraphysiological concentration of CCK (100 nM) or TPA to
stimulate PAK2.Both a representative experiment of 4 others and the means of all the ex-
periments are shown in each panel.Panel A: Rat pancreatic acinar cells were pretreated
with no additions or with IPA-3 (40 μM) or Pir 3,5 (40 μM) for 15min and then incubated
with no additions (control), with 0.3 nM or 100 nM CCK for 3 min or with 1 μM TPA for
5 min and then lysed and analyzed anti-pT402 PAK2 and, as a loading control, anti-total
PAK2. * p b 0.05 vs control, # p b 0.05 vs IPA-3 alone, ∞ p b 0.05 vs Pir 3,5 alone and $
p b 0.05 comparing stimulants (CCK or TPA) vs stimulants pre-incubated with IPA-3.Panel
B: Rat pancreatic acinar cells were pretreated with no additions or with PP2 (10 μM) or
PP3 (10 μM) for 1 h and then incubated with no additions (control), with 0.3 nM,
100 nM CCK for 3 min or with 1 μM TPA for 5 min and then lysed and analyzed anti-
pT402 PAK2 and, as a loading control, anti-total PAK2. * p b 0.05 vs control, # p b 0.05 vs
PP2 alone, ∞ p b 0.05 vs PP3 alone and $ p b 0.05 comparing stimulants (CCK or TPA) vs
stimulants pre-incubated with PP2.Panel C: Rat pancreatic acinar cells were pretreated
with no additions orwith wortmannin (1 μM) or Ly294002 (100 μM) for 30min and then
incubatedwith no additions (control), with 0.3 nM or 100 nM CCK for 3 min or with 1 μM
TPA for 5min and then lysed and analyzed anti-pT402 PAK2 and, as a loading control, anti-
total PAK2. * p b 0.05 vs control, # p b 0.05 vs wortmannin alone and ∞ p b 0.05 vs
LY294002 alone.
Table 2
Effect of PAK2 inhibition on amylase secretion.
Secretagogue Amylase secretion (% total)
IPA3 inhibitor 40 μM IPA3 40 μM Pir 3,5
None 3.8 ± 0.3 5.2 ± 0.5 4.3 ± 0.9
CCK (0.01 nM) 11.9 ± 2.2* 7.5 ± 1.3$ 12.6 ± 0.8*
CCK (0.1 nM) 15.7 ± 0.4* 9.6 ± 0.6$ 14.7 ± 1.0*
Bombesin (10 nM) 15.2 ± 0.8* 10.3 ± 0.9$ 14.4 ± 1.2*
Pancreatic acini were incubated with no additions, the indicated secretagogue alone or
with the active PAK2 inhibitor, IPA-3 (40 μM) or its inactive analog Pir 3,5 (40 μM). Amy-
lase release, expressed as percent of cellular total amylasewas determined after 30min in-
cubation. Results are the result of the average of 5–10 experiments. *p b 0.05 compared to
control, and $ p b 0.05 comparing stimulants (CCK or bombesin) vs stimulants at the same
concentration pre-incubated with IPA-3.
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The purpose of this study was to determine if Group-I-PAK kinases
are present in pancreatic acinar cells, and if so, are they activated by
GI hormones/neurotransmitters and growth factors, and to determine
the transduction cascades involved. In various tissues, PAKs are activat-
ed by a wide range of stimuli [2,2,9,10,19–21,30,36,63–67] and a num-
ber of G-protein-coupled-receptors [26,68]. However, little is known
of their ability to be activated by GI hormones/neurotransmitters or if
so, the cellular signaling cascades involved. To address this question
we studied pancreatic acinar cells because these cells respond to a
large number of GI hormones/neurotransmitters and GI growth factors
[33,69]. Particular attentionwas paid to the GI hormone/neurotransmit-
ter cholecystokinin, CCK, because it is both a physiological regulator of
pancreatic function [37] and plays an important role in a number of
pathophysiological processes, such as pancreatitis and response to inju-
ry [37,38,70,71].
In regards to the pancreas, except in the case of islet function [16,24,
35], there are no studies examining the presence of PAKs in exocrine tis-
sues and their activation or signaling has not been investigated. Howev-
er, previous studies report CCK activates the small GTP binding proteins,
Rho and Rac1,which are one of themain stimulants of PAKs in other tis-
sues [13]. Furthermore, activation of Ras and Rho in acinar cells is im-
portant in enzyme secretion as well as in mediating various pathologic
effects on the morphology of the acinar cell occurring in CCK-induced
experimental models of acute pancreatitis [72–74]. In the case of pan-
creatic cancer, a number of studies have reported PAK1 and PAK4 acti-
vation promote pancreatic acinar cell growth and effects on survival
[75,76] and that PAK1 expression is an important prognostic marker
of pancreatic cancer [76].
In this studywe established that PAK2 is the only Group-I-PAK pres-
ent in rat pancreatic acini. This result differs from ﬁndings in pancreatic
islets, which are reported to contain PAK1 inmurine [16,24] and human
islets [35] and from results in embryonic islet β cells, which contain
PAK3 [17].
Previous results have demonstrated that numerous GI growth fac-
tors (HGF, EGF, bFGF, insulin, IGF and PDGF) are able to interact with
speciﬁc receptors on pancreatic acinar cells and stimulate growth and/
or protein synthesis as well as alter other cellular functions [33,33,54,
57,77–79]. We observed activation of PAK2 by EGF, bFGF and PDGF,
but not by insulin, IGF-1 and HGF. This result has both similarities and
differences from studies of the effects of the growth factors in other tis-
sues. In contrast to our results, in NIH-3T3 [22], prostate cancer [80] or
epithelial cells [13,81], neither EGF nor FGF activated PAK1/PAK2,
whereas HGF did [22]. Moreover, in contrast to our results, Group-I-
PAKs mediate IGF-1 signaling in mesothelial cells [23] and insulin sig-
naling in mouse endocrine L cells [24]. Similar to our results, PDGF
stimulated PAK1 and PAK2 in NIH-3T3 cells, whereas insulin did
not [22]. Also, in epidermal cells EGF activated PAK2 [25] as well as
stimulating PAK1 in Cos7 cells [26]. Similarly, in PC-12 cells [27–29]
bFGF stimulated cell growth by activating PAK1/PAK2. These resultsdemonstrate that growth factors' ability to activate Group-I-PAKs can
vary markedly in different cells.
Our studies show that only the secretagogues stimulating PLC-
activated cascades resulting in changes of cytosolic calcium and PKC ac-
tivation (CCK, carbachol, bombesin), but not those activating adenylate
cyclase (VIP, secretin) [33,69,82,83], or other signaling cascades
(endothelin) [47,48], activate PAK2 in pancreatic acini. The failure of
the latter agents to activate PAK2was not due to the experimental con-
ditions used because each was used at concentrations and under exper-
imental conditions which are known to alter acinar cell function [33,47,
48,84]. Our results in pancreatic acini are similar to ﬁndings in vascular
smooth cells in which Group-I-PAKs are activated in a PLC-dependent
manner by angiotensin II [68,85], as well as Group-I-PAKs activation
by muscarinic cholinergic agents in ﬁbroblasts or neuroblastoma cells
[26] and in smooth muscle cells [86]. Similar to pancreatic acini,
endothelin did not activate Group-I-PAKs in myocytes [87]. Also, in var-
ious tissues, gastrin, which interacts with the high afﬁnity CCK2 recep-
tor, which is also coupled to PLC, stimulated Group-I-PAKs [31,88,89].
Our results are consistent with observations that CCK, in pancreatic
acini, stimulates, in a PLC-dependent manner [72], Rac1, which is a
PAK activator in other tissues [1,13]. In contrast to our results with se-
cretagogues activating cAMP failing to activate PAK2, in human
mesangial cells, endothelin activates CDC42, in a PKA-dependent man-
ner [22], and PKA activation is required for PAKs activation by other
GPCRs [90]. These results demonstrate that signaling cascades activat-
ing Group-I-PAKs show wide differences in different cells, even with
stimuli, which activate similar cellular-signaling cascades.
CCK stimulates several kinases in pancreatic acini and their kinetics
of activation can vary considerably [34,58,61,91–93]. We found that
the kinetics of CCK-stimulated PAK2 activation was similar to those ob-
served in pancreatic acini with the SFK, Yes, PKC theta, PYK2 and PKD
[41,54,77,94] in that it showed a rapid increase, which subsequently
partially decreased (by 40%), but was sustained over time. However, it
differed from CCK's activation of p125FAK or Lyn [39,78], which after ini-
tial stimulation decreases markedly to almost basal levels. The time
course of CCK-activation of PAK2 in our study differs from that reported
in most other tissues for PAK activation by various stimuli, where it is
generally much slower [18,26,95]. However, the CCK time-course for
PAK2 activation in pancreatic acini is similar to that of EGF-induced
PAK2-activation in COS7 cells [26]. These results demonstrate the kinet-
ics of activation of PAKs in different cells shows wide variation, even by
different stimuli in the same cell.
Numerous studies demonstrate that CCK can activate both high- and
low-afﬁnity receptor-states, which can mediate different cellular re-
sponses [34,38,96]. Our results show that activation of both receptor-
states is required for maximal PAK2 activation, because the CCK dose–
response curve for PAK2 activation included the concentration ranges
that activate, both high and low afﬁnity receptor-states [33,56,96].
Moreover, incubation with CCK-JMV, a full agonist at the high-afﬁnity
receptor state and an antagonist of the low-afﬁnity state [56,96], dem-
onstrated that 26% of PAK2 maximal CCK-stimulation is due to activa-
tion of the high-afﬁnity CCK1 receptor-state and 74% to activation of
the low-afﬁnity CCK1 receptor-state. Our results with PAK2 activation
are similar to the CCK-induced activation of the Src kinases (Lyn, Yes)
[41,78], the focal adhesion kinases (p125FAK, PYK2) [34,39], paxillin
[34,40] and PKD [54] in pancreatic acini [78], that are allmediated by ac-
tivation of both high- and low-afﬁnity receptor-states, although with
differences in their relative importance. In contrast to these results,
CCK-mediated activation in pancreatic acini of phospholipase D or
PI3K requires activation of only the high-afﬁnity receptor-state [97],
whereas in the case of PKC-δ [32] or CRK-II [98], only the low-afﬁnity
CCK1 receptor-state is required for activation. Also, a previous study
[99] reported CCK-stimulated SFK activity is mediated almost entirely
by activation of the low-CCK1 receptor state in pancreatic acini. Our re-
sults provide additional support to the proposal [94] that not only are
the different CCK1 receptor-states on pancreatic acini differentially
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adhesion kinases [33], they are also differentially coupled to activation
of small GTPases, Rac1/CDC42 leading to the activation of PAK2.
Activation of the pancreatic CCK1 receptor stimulates phospholipase
C (PLC), resulting in the generation of inositol phosphates and diacyl-
glycerol which in turn results in mobilization of cellular calcium and ac-
tivation of PKCs, respectively [33,34,38]. The experiments performed in
this study, including incubation with calcium ionophore, A23187 and
thapsigargin (TG) [34,100]; with the PKC activator, TPA; the inhibition
of increases of cytosolic Ca++ or PKC activity, and the combination of
Ca++ and PKC-modulating experiments, showed that activation of
PKC, but not changes in cytosolic calcium, by CCK1 receptor stimulation,
is an important mediator for the activation of PAK2 in pancreatic acini
and that 40% of the PKC-independent activation of PAK2 was also PLC-
independent. In some experiments A23187 had an apparent stimulato-
ry effect, however due to high variability, it was not statistically signiﬁ-
cant. However, as the combination of A23187, with the PKC activator,
TPA, did not cause greater activation than with any of these agents
alone, we conclude that A23187has no effect on PAK2. These results dif-
fer from the stimulatory effect of angiotensin II on Group-1-PAKswhich
in vascular smooth cells requires both limbs of the PLC cascade (PKC and
calcium) [68], whereas in other cell systems only increases in Ca2+ are
required [85]. Similarly, activation of COS cells bymuscarinic cholinergic
agents or LPA, stimulated Group-I-PAKs activation in a completely PKC-
independent manner [19]. In contrast, our results are similar to activa-
tion of Group-I-PAKs in neutrophil receptors by FMLP, which requires
activation of PKC, but not of cytosolic calcium [101]. These results dem-
onstrate that even with stimuli, which activate PLC in a number of dif-
ferent tissues, the relative importance of activation of the two limbs of
the PLC cascade (increases in Ca2+, PKC) in stimulating PAK activation
varies markedly.
In addition to small GTPases (Rac1, CDC42) PAK's activity can be af-
fected by activation of a number of signaling cascades [9,19,31,85,102,
103] and the participation of the various cascades can vary markedly
in different cells. However, there is almost no information on the signal-
ing cascades bywhich gastrointestinal hormones/neurotransmitters ac-
tivate PAKs. Our results demonstrate that in addition to PKC being
involved as an upstream activator of CCK- and TPA-induced activation
of PAK2, activation of SFKs at physiological CCK doses is important,
but not activation of PI3K. Our ﬁnding that the SFK inhibitor PP2,Fig. 8. Schematic diagram of signaling role of PAK2 in pancreatic acinar cells. In rat pancreatic ac
pholipase C resulting in PKC activation. PAK2 activation involves both PLC-dependent and indep
es in Ca++-not involved. PAK2 also requires SFK-dependent and SFK-independent signaling.
mediated by CCK-activation is CDC42/Rac1. On the other hand PAK2 is a mediator of CCK-medsigniﬁcantly inhibited the activation of PAK2 at a physiological CCK con-
centration (0.3 nM), but not at supramaximal concentrations (100 nM),
suggests that the activation of the high-afﬁnity CCK receptor state re-
quires SFKs for full PAK2 activation. The ﬁnding that under experimen-
tal conditions that inhibited completely SFKs [86], only partially
inhibition of PAK2 activation was seen, demonstrates that CCK, at phys-
iological concentrations, activates PAK2 by both SFK-dependent and in-
dependent mechanisms. Our ﬁndings with the involvement of SFK's in
PAK2 activation by CCK are novel in that they demonstrate both an ag-
onist concentration-dependent effect and receptor-state activation ef-
fect, as well as support for both SFK-dependent and independent
PAK2 activation. The lack of effect of PI3K inhibition in PAK2 activation
in pancreatic acini was not due to an inadequate inhibitory dose, be-
cause the inhibitor concentrations used were similar to that previously
reported in other tissues that are known to inhibit PI3K activation of
Akt. Similarly to reported in other tissues [14,104], the inhibition of
the binding of small GTPases to the activation domain of PAK2 by IPA-
3 incubation markedly inhibited the PAK2 activation, although, under
our experimental conditions, the inhibitionwas not complete. The spec-
iﬁcity of the IPA-3 inhibitory effectwas supported by the lack of effect of
the inactive control Pir 3,5 [59,68,105]. These results suggest that,
although the small GTPases are the principal upstream activator of
PAK2 in these cells, there may be additional mechanisms of activation
that involve PKC and/or SFKs, both which are important CCK signaling
pathways in pancreatic acinar cells [58,77,105]. These results differ from
that observed in COS7 [102], HeLa [9], A2058 human melanoma [19]
and colorectal cells [31] where the activation of PAK by different stimuli
requires activation of PI3K. Also similar to our results, SFK activation is
needed for increased PAK1 activity in hippocampal neurons [103]. How-
ever, in smoothmuscle cells SFK activationwas not needed for the angio-
tensin II-mediated activation of PAK [85]. These ﬁndings that activation of
SFKs is frequently upstreamof PAKs activation are consistentwith studies
demonstrating SFKs are important in the activation of the PAK activators,
Rac and CDC42, by a number of stimulants [103,106,107]. These results
reveal that the GI hormone/neurotransmitter, CCK, demonstrates a num-
ber of unique features related to its receptor activation-state in activating
signaling cascades to stimulate PAK2 activation.
CCK stimulates both enzyme secretion by pancreatic acinar cells, as
well as their growth [33,38]. The activation of Rac by CCK has been
shown to be important for the pancreatic enzyme secretion [72] andinar cells maximal activation of PAK2 by CCK requires activation of CDC42/Rac1 and phos-
endent cascadeswith the PLC-dependent cascademediated by PKC activation,with chang-
However, changes in PI3K are not involved, but a major component of PAK2 activation
iated ERK1/2 activation.
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acinar cells [38,108]. With some cells such as the stimulation by LPS of
rat ﬁbroblasts [109], prolactin in breast cancer cells [110] or 12-HETE
in CHO cells [111], the activation of Group-I-PAKs is needed for the acti-
vation of ERK. These observations raise the possibility that activation of
PAK2 by Rac could also be essential for CCK-mediated enzyme secretion
and activation of ERK in pancreatic acini, subsequently resulting in
growth. To determine whether this in fact occurs, we examined the ef-
fect of the speciﬁc Group-I-PAKs inhibitor on the ability of CCK to acti-
vate both ERK1/2 and stimulate enzyme secretion. We found that
activation of PAK2 by CCK was needed for both enzyme secretion stim-
ulated by CCK or bombesin as well as the ability of CCK to activate the
MAP kinase, ERK1/2. Our ERK results are consistent with studies in
other cells reporting that activation of PAKs by growth factors [22], gas-
trin [31], prolactin [112] or biological active lipids [18] result in ERK ac-
tivation. In contrast to our results, the activation of ERK1/2 in skeletal
muscle cells is independent of PAK1 [113]. In addition, to these results
demonstrating activation of PAK2 is important in mediation of two of
CCK's physiological effects on pancreatic acini, they also raise the possi-
bility that PAK2 activation may be important in the pathophysiological
effects of CCK. The latter hypothesis is supported by studieswhich dem-
onstrate that in the CCK model of acute pancreatitis, the activation of
Rac as well as Rho is essential for the characteristic morphologic effects
which occur and the actin-distribution which accompanies these
changes [73,114].
In conclusion, our study demonstrates pancreatic acinar cells pos-
sess only one member of the Group-I-PAKs, PAK2, which differs from
the ﬁnding in pancreatic islets in a number of previous studies [16,17,
24]. Furthermore, a number of GI growth factors as well as GI hor-
mones/neurotransmitters, which activate PLC, can activate the PAK2.
The results of our cell signaling studies are summarized in Fig. 8. CCK
stimulated PAK2 activation is novel in that it involves both PLC-
dependent and -independent cascades and the PLC-dependent cascade
aremediated by PKC activationwith no involvement of changes in cyto-
solic calcium. Furthermore, activation of SFK is partially required for the
PKC-mediated PAK2 activation, but in contrast to a number of other
cells, PI3K activation is not needed. CCK also activates PAK2 through a
CDC42/Rac1, dependent cascade. PAK2 is also important in mediating
ERK1/2 activation and amylase release. Our results support the conclu-
sion that activation of PAKs in pancreatic acinar cells by GI hormones/
neurotransmitters and GI growth factors may be an important signaling
cascade in both physiological and pathophysiological responses in the
case of pancreatic acinar cells. The importance of PAKs in the pancreatic
acinar cell pathologic conditions is supported by recent studies demon-
strating that inhibition of Rac activation, one of the PAK's main up-
stream activators, decreases the severity of pancreatitis [114] or by
studies demonstrating activation of PAK4 in the pancreatic acinar cell
line, AR42J, is associated with activation of intracellular trypsinogen,
one of the main mediators of acute pancreatitis [36]. These support
the idea that PAK's could be a potential target for the treatment of
acute pancreatitis.
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